Phase I Study of Yttrium-90 Radiolabeled M5A Anti-Carcinoembryonic Antigen Humanized Antibody in Patients with Advanced Carcinoembryonic Antigen Producing Malignancies-Reference-Cited by-同舟云学术

Phase I Study of Yttrium-90 Radiolabeled M5A Anti-Carcinoembryonic Antigen Humanized Antibody in Patients with Advanced Carcinoembryonic Antigen Producing Malignancies

Published:2020-02-01 Issue:1 Volume:35 Page:10-15
ISSN:1084-9785
Container-title:Cancer Biotherapy and Radiopharmaceuticals
language:en
Short-container-title:Cancer Biotherapy and Radiopharmaceuticals

Author:

Akhavan David¹,Yazaki Paul²,Yamauchi Dave³,Simpson Jennifer⁴,Frankel Paul H.⁵,Bading James²,Colcher David²,Poku Kofi²,Chen Yi-jen¹,Lim Dean⁴,Cristea Mihaela⁴,Wu Anna²,Shively John²,Wong Jeffrey Y.C.¹

Affiliation:

1. Department of Radiation Oncology, City of Hope National Cancer Center, Duarte, California.

2. Department of Molecular Imaging and Therapy, Beckman Research Institute, Duarte, California.

3. Department of Diagnostic Radiology, City of Hope National Cancer Center, Duarte, California.

4. Department of Medical Oncology, City of Hope National Cancer Center, Duarte, California.

5. Department of Information Sciences, City of Hope National Cancer Center, Duarte, California.

Publisher

Mary Ann Liebert Inc

Subject

Cancer Research,Pharmacology,Radiology, Nuclear Medicine and imaging,Oncology,General Medicine,Cancer Research,Pharmacology,Radiology, Nuclear Medicine and imaging,Oncology,General Medicine

Link

https://www.liebertpub.com/doi/pdf/10.1089/cbr.2019.2992

Reference24 articles.

1. Phase I/II 90 Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin's lymphoma

2. Efficacy and Safety of Tositumomab and Iodine-131 Tositumomab (Bexxar) in B-Cell Lymphoma, Progressive After Rituximab

3. A Phase I Study of a Combination of Yttrium-90–Labeled Anti–Carcinoembryonic Antigen (CEA) Antibody and Gemcitabine in Patients with CEA-Producing Advanced Malignancies

4. 90 Y-clivatuzumab tetraxetan with or without low-dose gemcitabine: A phase Ib study in patients with metastatic pancreatic cancer after two or more prior therapies

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evaluation of a novel 177Lu-labelled therapeutic Affibody molecule with a deimmunized ABD domain and improved biodistribution profile;European Journal of Nuclear Medicine and Molecular Imaging;2024-07-15

2. Targeting Patient-Derived Orthotopic Gastric Cancers with a Fluorescent Humanized Anti-CEA Antibody;Annals of Surgical Oncology;2024-06-18

3. CEACAM5-Targeted Immuno-PET in Androgen Receptor–Negative Prostate Cancer;Journal of Nuclear Medicine;2024-05-23

4. Humanized Anti-Carcinoembryonic Antigen Antibodies Brightly Target and Label Gastric Cancer in Orthotopic Mouse Models;Journal of Surgical Research;2024-01

5. PEGylated Fluorescent Anti-carcinoembryonic Antigen Antibody Labels Colorectal Cancer Tumors in Orthotopic Mouse Models;Journal of Surgical Research;2023-11